Journal article · 2025 · Open access
Pharmacogenomics in Personalized Medicine Approaches
International Journal of Life Sciences Biotechnology and Pharma Sciences · Published 1 September 2025 · DOI 10.62648/v21.i04.2025.pp10-18
In brief
“Pharmacogenomics in Personalized Medicine Approaches” is a 2025 journal article by Oscar Kovacs, published in International Journal of Life Sciences Biotechnology and Pharma Sciences. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at International Journal of Life Sciences Biotechnology and Pharma Sciences.
- Citations
- 0
- References
- 18
- Authors
- 1
Abstract
Pharmacogenomics--the study of how genetic variation influences individual drug response in terms of efficacy, toxicity,and dosing requirements--has transitioned from a research discipline to a clinical standard of care across oncology,psychiatry, cardiology, and infectious disease over the past two decades, driven by the declining cost of genotyping andthe accumulating body of clinically actionable pharmacogenomic (PGx) associations validated in prospective trials. Thisreview comprehensively surveys the current landscape of pharmacogenomics in personalised medicine, covering: themolecular basis of PGx variation in drug-metabolising enzymes (CYP450 family, UGT1A1, TPMT, DPYD), drugtransporters (SLCO1B1, ABCB1), and drug targets (VKORC1, EGFR, KRAS, HER2); clinical implementation evidencefrom landmark trials including CPIC guideline-supported drug-gene pairs; the expanding role of polygenic risk scores(PRS) in drug response prediction beyond single-variant pharmacogenomics; current clinical decision support integrationchallenges; and the regulatory and health economic framework for PGx-guided prescribing. Key clinically validatedexamples reviewed include: warfarin dosing guided by CYP2C9/VKORC1/CYP4F2 genotype (reducing serious bleedingevents by 31-43%); clopidogrel response prediction by CYP2C19 loss-of-function alleles (associated with 3.58-foldincreased MACE risk in poor metabolisers); DPYD genotyping before fluoropyrimidine chemotherapy (reducing severetoxicity from 35% to 4.7%); and HER2/KRAS/BRAF tumour genotyping directing targeted therapy selection in metastaticcolorectal and breast cancer. Remaining implementation barriers including incomplete population diversity in PGxreference datasets, clinical workflow integration complexity, and reimbursement heterogeneity across Europeanhealthcare systems are critically evaluated alongside emerging opportunities from direct-to-consumer genomics,preemptive panel genotyping, and AI-guided phenotype prediction.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Kovacs, O. (2025). Pharmacogenomics in Personalized Medicine Approaches. International Journal of Life Sciences Biotechnology and Pharma Sciences. https://doi.org/10.62648/v21.i04.2025.pp10-18
MLA 9
Kovacs, Oscar. “Pharmacogenomics in Personalized Medicine Approaches.” International Journal of Life Sciences Biotechnology and Pharma Sciences, 2025. https://doi.org/10.62648/v21.i04.2025.pp10-18.
Chicago
Kovacs, Oscar. 2025. “Pharmacogenomics in Personalized Medicine Approaches.” International Journal of Life Sciences Biotechnology and Pharma Sciences. https://doi.org/10.62648/v21.i04.2025.pp10-18.
Harvard
Kovacs, O. (2025) ‘Pharmacogenomics in Personalized Medicine Approaches’, International Journal of Life Sciences Biotechnology and Pharma Sciences. doi:10.62648/v21.i04.2025.pp10-18.
IEEE
O. Kovacs, “Pharmacogenomics in Personalized Medicine Approaches,” International Journal of Life Sciences Biotechnology and Pharma Sciences, 2025, doi: 10.62648/v21.i04.2025.pp10-18.
BibTeX
@article{kovacs2025pharmacogenomics,
title = {{Pharmacogenomics in Personalized Medicine Approaches}},
author = {Kovacs, Oscar},
journal = {International Journal of Life Sciences Biotechnology and Pharma Sciences},
year = {2025},
doi = {10.62648/v21.i04.2025.pp10-18},
url = {https://doi.org/10.62648/v21.i04.2025.pp10-18}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- pharmacogenomics
- personalized medicine
- drug-metabolizing enzymes
- drug transporters
- drug response prediction
- polygenic risk score
- clinical decision support
- warfarin dosing
Work with this paper
Most-cited papers in Pharmacology, Toxicology and Pharmaceutics
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingOleg Trott, Arthur J. Olson · Journal of Computational Chemistry · 2009 · 39,860 citations
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityGarrett M. Morris, Ruth Huey, William Lindstrom and 4 more · Journal of Computational Chemistry · 2009 · 26,508 citations
- Development and testing of a general amber force fieldJunmei Wang, Romain M. Wolf, James W. Caldwell and 2 more · Journal of Computational Chemistry · 2004 · 20,080 citations
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy and 1 more · Advanced Drug Delivery Reviews · 2001 · 19,638 citations
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesAntoine Daina, Olivier Alain Michielin, Vincent Zoete · Scientific Reports · 2017 · 19,557 citations
All highly cited Pharmacology, Toxicology and Pharmaceutics papers
Questions about this paper
How do I cite this paper in APA style?
Kovacs, O. (2025). Pharmacogenomics in Personalized Medicine Approaches. International Journal of Life Sciences Biotechnology and Pharma Sciences. https://doi.org/10.62648/v21.i04.2025.pp10-18
How many times has this paper been cited?
0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at International Journal of Life Sciences Biotechnology and Pharma Sciences: sign in and open the PDF from this page.
Who wrote this paper?
Oscar Kovacs.
What is the DOI of this paper?
10.62648/v21.i04.2025.pp10-18, permanently at https://doi.org/10.62648/v21.i04.2025.pp10-18. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.